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VEGF-dependent induction of CD62E on endothelial cells
mediates glioma tropism of adult haematopoietic progenitor cells
Abstract
Haematopoietic progenitor cells (HPC) are attracted by experimental gliomas in vivo. This attraction is
further enhanced by irradiation or hypoxic preconditioning of the glioma cells. Adhesive interactions
might be critical to the preferential accumulation of HPC within the glioma tissue. Here, we studied the
interactions of HPC with endothelial cells. Exposure of human cerebral endothelial cells (SV-HCEC),
human microvascular endothelial cells (HMEC) and brain tumour endothelial cells derived from human
glioblastomas (BTEC) to supernatants of glioma cells and primary glioma cells (SN-G) induced the
expression of E-selectin (CD62E). CD62E expression was further enhanced when the glioma cells had
been exposed to irradiation or hypoxia prior to the collection of supernatants, as well as by irradiation or
exposure to hypoxia of the endothelial cells. Vascular cell adhesion molecule 1 (VCAM-1) was
constitutively expressed on SV-HCEC, HMEC and BTEC, but was not modulated by SN-G, irradiation
or hypoxia. Transendothelial HPC migration was enhanced after CD62E induction in vitro. Neutralizing
antibodies to CD62E strongly reduced the homing of lin(-)Sca-1(+)c-kit(+) cells to orthotopic SMA-560
gliomas in vivo. Tissue microarray sampling normal brain tissue and astrocytomas of WHO grades II-IV
revealed a selective expression of CD62E on endothelial cells of tumour vessels. SN-G-induced CD62E
expression on endothelial cells in vitro required transforming growth factor (TGF)-beta signalling in
glioma cells and vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGF-R2) signalling in
endothelial cells. Further, we observed a nuclear factor kappa B-dependent activation of the CD62E
promoter peaking at 12 h after VEGF-R2 activation by glioma-derived VEGF. Taken together, we
identify glioma cell-induced CD62E expression on endothelial cells as one mediator of the glioma
tropism of HPC.
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Abstract  
Hematopoietic progenitor cells (HPC) are attracted by experimental gliomas in vivo. This 
attraction is further enhanced by irradiation or hypoxic preconditioning of the glioma 
cells. Adhesive interactions might be critical to the preferential accumulation of HPC 
within the glioma tissue. Here, we studied the interactions of HPC with endothelial cells. 
Exposure of human cerebral endothelial cells (SV-HCEC), human microvascular 
endothelial cells (HMEC) and brain tumor endothelial cells derived from human 
glioblastomas (BTEC) to supernatants (SN) of glioma cells and primary glioma cells 
(SN-G) induced the expression of E-selectin (CD62E). CD62E expression was further 
enhanced when the glioma cells had been exposed to irradiation or hypoxia prior to the 
collection of SN, as well as by irradiation or exposure to hypoxia of the endothelial cells. 
Vascular cell adhesion molecule 1 (VCAM 1) was constitutively expressed on SV-HCEC, 
HMEC and BTEC, but was not modulated by SN-G, irradiation or hypoxia. 
Transendothelial HPC migration was enhanced after CD62E induction in vitro. 
Neutralizing antibodies to CD62E strongly reduced the homing of lin-Sca1+Kit1+ cells to 
orthotopic SMA-560 gliomas in vivo. Tissue microarrays sampling normal brain tissue 
and astrocytoma of WHO grade II-IV revealed a selective expression of CD62E on 
endothelial cells of tumor vessels. SN-G-induced CD62E expression on endothelial cells 
in vitro required transforming growth factor (TGF)-β signaling in glioma cells and 
vascular endothelial growth factor (VEGF)-VEGF-receptor 2 (VEGF-R2) signaling in 
endothelial cells. Further, we observed a nuclear factor kappa B (NFκB)-dependent 
activation of the CD62E promoter peaking at 12 h after VEGF-R2 activation by glioma-
derived VEGF. Taken together, we identify glioma cell-induced CD62E expression on 
endothelial cells as one mediator of the glioma tropism of HPC.
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Abbreviations:  
BM = bone marrow; BTEC = brain tumor endothelial cells isolated from human 
glioblastoma tissue; CXCL12 = CXC chemokine ligand 12; CD = cluster of 
differentiation; CD62E = E-selectin; CD62P = platelet selectin; DAPI = 4`,6-diamidino-2-
phenylindole; ELISA = Enzyme-linked immunosorbent assay; EPC = endothelial 
progenitor cells; FCS = fetal calf serum; G-CSF = granulocyte colony stimulating factor; 
HIF = hypoxia-inducible factor; HMEC = human microvascular endothelial cells, HPC = 
hematopoietic progenitor and stem cells; IL = interleukin; LSK = lineage-depleted Sca1+ 
Kit+ murine HPC; NFκB = nuclear factor kappa B; NT = no treatment; pVEGF-R2 = 
phosphorylated VEGF-R2; sKitL = soluble Kit ligand; sCD62E = soluble E-selectin; SCF 
= stem cell factor; SDF = stromal cell-derived factor; SN = supernatant; SN-308-co = SN 
of LN-308 glioma cells transiently transfected with non-targeting control pool siRNA; SN-
308-siTGF-β1,2 = SN of LN-308 transiently co-transfected with siRNA pools targeting 
TGF-β1 and TGF-β2; SN-G = SN of glioma cell lines LNT-229; LN-308 and primary 
glioma cultures T113, T132, T159; SN-Gp = SN of LNT-229 puro cells; SN-GpSD-208 = 
SN of SD-208-treated LNT-229 puro cells; SN-G-siTGF-β = SN of LNT-229 siTGF-β1,2 
cells stably expressing shRNAs targeting TGF-β1 and TGF-β2; SN-FHAS = SN of SV-
FHAS cells, SN-GRT = supernatant of irradiated glioma cells, SN-GHO = supernatant of 
hypoxic glioma cells; SFM = serum-free medium; SFI = specific fluorescence index; SV-
HCEC = human cerebral endothelial cells; SV-FHAS = human astrocytic cell line; TGF-β 
= transforming growth factor beta; TNF-α = tumor necrosis factor alpha; VCAM = 
vascular cell adhesion molecule; VEGF = vascular endothelial growth factor; VEGF-R = 
VEGF receptor.  
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Introduction 
Intracerebral experimental gliomas attract intravenously injected CD34+ hematopoietic 
progenitor and stem cells (HPC). The underlying molecular pathways leading to the 
glioma tropism of HPC involve a transforming growth factor (TGF)-β-dependent 
signaling cascade regulating the release of stromal cell-derived factor (SDF)-1α/CXC 
chemokine ligand 12 (CXCL12) by glioma cells. CXCL12 interacts with the chemokine 
receptor CXCR4 on HPC. Further, matrix metalloproteinase (MMP)-9 cleaves and 
thereby releases soluble Kit ligand (sKitL) which interacts with the receptor CD117 on 
HPC (Tabatabai et al., 2005). Cerebral irradiation promotes the homing of HPC to the 
tumor bulk and to tumor satellites in vivo. Supernatants (SN) of irradiated or hypoxic 
glioma cells enhance the HPC migration in vitro due to a TGF-β-dependent, hypoxia-
inducible factor-1 α (HIF-1α)-mediated induction of CXCL12 promoter activity in glioma 
cells (Tabatabai et al., 2006). CXCL12 is also an important mediator for the attraction of 
mesenchymal stem cells to experimental gliomas (Nakamizo et al., 2005). A systemic 
gradient of CXCL12 alone, however, might not be sufficient to explain the glioma-
mediated attraction of intravenously injected HPC. Moreover, further insight into the 
mechanism of the glioma tropism is required for the design of a HPC-based cellular 
therapy that specifically targets gliomas.  
The regional expression of endothelial adhesion molecules may contribute to the 
specificity of HPC homing towards gliomas. Similarities in the trafficking and homing of 
HPC and leukocytes to particular tissue sites arise. The diapedesis of leukocytes to sites 
of infection and inflammation is an important step in their recruitment. This process 
ensures appropriate innate and adaptive immunological responses. Adhesion molecules 
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mediate rolling and arrest of leukocytes on the vessel wall as key steps prior to the 
transmigration across the endothelial layer (Millan et al., 2006; Nieminen et al., 2006).  
Adhesion is also critical for the interaction of HPC within the hematopoietic 
microenvironment in the bone marrow (BM). Important mediators of this adhesive 
interaction include vascular cell adhesion molecule 1 (VCAM-1), platelet selectin 
(CD62P) and endothelial selectin (CD62E) (Frenette et al., 1998; Katayama et al., 
2003). CD62P is deposited in storage granules of platelets and endothelial cells. After 
activation, it is translocated to the surface (Bevilacqua et al., 1989). VCAM-1 and CD62E 
are solely expressed on endothelial cells (Mazo et al., 1998). In this study, we analyzed 
the role of HPC adhesion to endothelial cells in the glioma tropism of HPC. 
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Material and Methods 
Cell culture 
Human adult HPC were isolated by anti-CD34 immunomagnetic microbeads (Bautz et 
al., 2001). After informed consent, peripheral blood cells were obtained from healthy 
donors or patients with non-hematological malignancies during G-CSF-induced stem cell 
mobilization, according to the guidelines of the ethics committee of the University of 
Tübingen (project number 268/2003-LP). The human CD34 antigen is a reliable marker 
for identifying a small fraction of human bone marrow and peripheral blood mononuclear 
cells consisting of primitive uncommitted and pluripotent hematopoietic progenitor cells 
as well as hematopoietic stem cells (Andrews et al., 1986; Berenson et al., 1988; 
Terstappen et al., 1991; Van Epps et al., 1994; Albo et al., 2004). The source, 
generation and culture conditions of the cerebral vascular endothelial cell line SV-HCEC 
and the astrocytic cell line SV-FHAS have been described (Muruganandam et al., 1997). 
Brain tumor endothelial cells (BTEC) were isolated from freshly resected human 
glioblastomas and characterized for their endothelial cell phenotype as described 
(Miebach et al., 2006). Briefly, the tissue was minced, homogenized, and digested 
enzymatically. The cells were separated by percoll gradient centrifugation. CD31-
positive cells were isolated by magnetic beads (Dynal, Hamburg, Germany). Only 
passages 0-2 cells were used for the experiments. Human microvascular endothelial 
cells (HMEC) were purchased from Cascade Biologics (Invitrogen GmbH, Karlsruhe, 
Germany). All glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, 
Switzerland). In contrast to other LN-229 sublines, LN-229 glioma cells cultured in our 
laboratory exhibit wild-type p53 status (Wischhusen et al., 2003) and are designated 
LNT-229. The generation of LNT-229 sublines stably depleted from TGF-β1 and TGF-β2 
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by RNA interference (LNT-229 siTGF-β1,2) and the control cells (LNT-229 puro) has 
been described (Friese et al., 2004). The following primary glioma cultures were used: 
T113, T159, derived from glioblastomas, and T132, derived from an anaplastic 
astrocytoma. The primary human glioma cultures were established from samples with 
high tumor content (Bähr et al., 2003). SN of glioma cells (SN-G) were generated in 
serum-free medium (SFM): 1.5 million glioma cells were first seeded in serum-containing 
medium in T75 cell culture flusks. The medium was removed on the next day, the cells 
were washed three times with PBS. Seven ml SFM was added, 48 h later, SN were 
harvested. Concentration of SN was performed with the Centriplus centrifugal filter 
device YM-3 (3 kD cut-off, Millipore, Eschborn, Germany). Protein quantification was 
performed by Bradford assay (BioRad, Munich, Germany). Treatment of endothelial cells 
with SN-G was performed for 6, 12, 24, 48 or 96 h. Incubation of cells in hypoxia was 
performed at 37°C and 1% O2 for 6, 12, 24, 48 or 96 h (Wick et al., 2002a). Cells were 
irradiated at 2 or 8 Gy (γ-Cell, Nordion, Kanata, CA, USA) and analyzed at 6, 12, 24, 48 
or 96 h thereafter (Wick et al., 2002b). Recombinant TGF-β2 and VEGF165, neutralizing 
antibodies to VEGF (clone 26503) and VEGF-R2 (clone 89106) were purchased from 
R&D Systems (Wiesbaden-Nordenstadt, Germany). SD-208 was provided by Scios 
(Fremont, CA, USA) (Uhl et al., 2004). siRNA pools targeting human TGF-β1, TGF-β2 or 
VEGF containing four selected siRNA duplexes each with a modification pattern that 
addresses off-target effects caused by both strands (ON-TARGETplus SMARTpool) and 
the non-targeting control pool (ON-TARGETplus siCONTROL Non-targeting Pool) were 
designed by and purchased from Dharmacon (Lafayette, CO, USA). The pool of siRNA 
duplexes targeting TGF-β1 had the following sense sequences: 5’-
AUUGAGGGCUUUCGCCUUAUU-3’, 5’-CCGAGAAGCGGUACCUGAAUU-3’, 5’-
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GCAGAGUACACACAGCAUAUU-3’,  5’-GTGACUAUCCACCUGCAAGAUU-3’. The 
siRNA duplexes targeting TGF-β2 had the following sense sequences: 5’-
GGAUUGAGCUAUAUCAGAUUU-3’, 5’-CUGCGUGUCCCAAGAUUUAUU-3’; 5’-
GAUGCGGCCUAUUGCUUUAUU-3’, 5’-GAGCAUGCCCGUAUUUAUGUU-3’. The 
siRNA duplexes targeting VEGF had the following sense sequences: 5`-
GCAGAAUCAUCACGAAGUG, 5`-CAACAAAUGUGAAUGCAGA, 5`-
GGAGUACCCUGAUGAGAUC, 5`-GAUCAAACCUCACCAAGGC. Lipophilic 
transfection was performed with Metafectene Pro (Biontex, Martinsried, Germany).  
 
Transendothelial migration of HPC 
Migration assays were performed in transwell plates (Costar; Cambridge, MA, USA) of 
6.5 mm diameter, with 5 μm pore filters. SV-HCEC, HMEC or BTEC were plated at 105 
cells/transwell on filters coated with fibronectin. Nonadherent cells were removed after 
24 h. The adherent cells were cultured for 48 h to obtain confluent endothelial 
monolayers. Confluency of the endothelial monolayers was confirmed by measuring 
permeability for albumin (Möhle et al., 1997). The monolayers were used unstimulated, 
stimulated with SN-G or after exposure to irradiation or hypoxia. Prior to the migration 
experiment, the monolayer was washed three times with PBS. 105 CD34+ HPC in 200 µl 
SFM were added to the upper compartment. SFM, recombinant CXCL12 or SN-G were 
added to the lower compartment. In neutralization experiments, the SV-HCEC were 
preincubated for 4 h at 37°C with α-CD62E (R&D, clone BBIG-E4[5D11]) or α-VCAM-1 
(R&D, clone BBIG-V1 [4B2]) or appropriate control antibodies. Migration was assessed 
at 37°C, 5% CO2 for 16 h. Cells that had migrated to the lower compartment were 
quantified with the CyQuant Assay (Invitrogen, Karlsruhe, Germany).  
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 Reporter assays 
For dual luciferase/renilla assays (Dyer et al., 2000) 200 ng of the respective reporter 
constructs was cotransfected with 20 ng of pRL-CMV. pGL3b.CD62E contains the full-
length promoter of CD62E (Nubel et al., 2004). pNFκB-Luc contains a firefly luciferase 
gene that is especially designed for the detection of NFκB signal transduction pathway 
activity. It contains four copies of the NFκB consensus sequence fused to a TATA-like 
promoter region from the Herpes simplex virus thymidine kinase promoter. The binding 
of endogenous NFκB leads to induction of transcription and activation of the reporter 
gene in the transfected cells indicating transcriptional activity of NFκB. Ad-IkBM and Ad-
Mock were kindly provided by Dr. P. A. Baker (McGill University, Ottawa, Canada). 
 
TransAM NFκB family 
Nuclear extracts were prepared (Nuclear Extract Kit, Active Motif, Rixensat, Belgium) 
from SV-HCEC, HMEC and BTEC and the transcriptional activity of the NFκB family 
p50, p65, p52, c-Rel and RelB by the transcripton factor assay TransAM NFκB family 
(Active Motif) was analyzed according to manufacturers`s protocol.  
 
Immunoblot 
Immunoblots were performed as described (Tabatabai et al., 2006). The following 
antibodies were used: phospho-Smad 2 (Ser 465/467), total Smad 2 (Cell Signaling, 
Boston, MA, USA), NFκB p50 and p65 (Santa Cruz, CA, USA), and GAPDH (Chemicon, 
Billerica, MA, USA). 
 
-9- 
Enzyme-linked immunosorbent assay (ELISA) 
The concentrations of VEGF, sCD62E, TGF-β1 and TGF-β2 in the SN were determined 
by Quantikine Immunoassays from R&D Systems. A sandwich ELISA was performed to 
measure the levels of phosphorylated VEGF-R2 and total VEGF-R2 in cell lysates (Duo 
Set IC, R&D Systems). The proliferation of cells was assessed by a cell proliferation 
biotrak ELISA system (GE Healthcare, Buckinghamshire, UK). 
 
Flow cytometry 
SV-HCEC, HMEC or BTEC were grown in 12-well plates either untreated or stimulated 
with the indicated SN, hypoxia or irradiation for 6, 12, 24, 48 or 96 h. Flow cytometry 
was performed with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg, 
Germany) (Eisele et al., 2006). The following antibodies (R&D Systems) were used: anti-
human CD62E, VEGF-R2 and VCAM-1. Signal intensity was calculated by dividing 
mean fluorescence obtained with specific antibody divided by signal intensity obtained 
with the isotype control antibody (specific fluorescence index, SFI). 
 
Human tissue samples and tissue microarray 
We investigated a total of 120 glioblastoma samples (WHO Grade IV) from 88 patients 
obtained from the tumor bank of the Institute of Neuropathology, University of Tuebingen 
derived from patients who underwent surgical treatment from 1993 to 2003 at the 
Department of Neurosurgery in Tuebingen or in the Department of Neurosurgery in 
Seesen. Diffuse astrocytomas WHO grade II (n=10) and anaplastic astrocytomas WHO 
grade III (n=10) were investigated. Shortly after surgical removal, all specimens were 
fixed with 4% formalin (pH 7.4) and subsequently embedded in paraffin followed by 
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preparation as tissue microarray (TMA) (Warth et al., 2006). Further, 60 samples from 
33 autopsy cases of a normal brain bank were added. Clinical data are summarized in 
tables 3. The tumor and normal brain tissues were stained with H&E and antibodies to 
CD31 (Dako Cytomation, Glostrup, Denmark), to CD62E (R&D Systems) or the 
respective isotype control antibodies. 
 
Animal studies 
On day 0, 104 SMA-560 cells were stereotactically implanted into the right striatum of 
VM/Dk mice. On day 7, LSK were isolated from BM of VM/Dk mice as described 
(Tabatabai et al., 2005). Briefly, femora and tibiae of VM/Dk mice were flushed with 2% 
FCS-containing PBS, erythrocytes were lysed, BM cells were incubated for 60 min at 
4°C with the lineage marker antibodies rat anti-mouse CD4, CD8a, CD45R/B220, Gr-1, 
CD11b and TER119 (BD Biosciences Pharmingen, San Diego, CA, USA), then washed 
with PBS prior to the addition of prewashed sheep anti-rat IgG magnetic beads 
(Dynabeads, Dynal, Biotech ASA, Oslo, Norway) at a 4:1 ratio of beads/cells. After 45 
min, beads and attached cells were magnetically removed. The remaining lineage-
depleted (lin-) cells were sorted with anti- Sca1+-beads by MACS (Miltenyi Biotech, 
Bergisch Gladbach, Germany). The check of purity by flow cytometry revealed that < 5 
% of the isolated LSK expressed CD4, CD8, CD11b, B220 or Gr-1. LSK were between 
95 and 98 % positive for Sca1 and >99% positive for c-kit (BD Biosciences 
Pharmingen). The LSK were cultured with murine IL-3 (20 ng/ml), IL-6 (50 ng/ml) and 
SCF (50 ng/ml) (R&D Systems) over night. On day 8, neutralizing rat anti-mouse CD62E 
(BD Bioscience, clone 10E9.6) or control antibodies were bolus-injected intraperitoneally 
(200 µl) and intratumorally (5 µl). Four hours later, PKH-26 (Sigma-Aldrich, Taufkirchen, 
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Germany) stained LSK were injected intraveneously. On day 10, mice were sacrificed. 
From each experimental group, 3 brains were analyzed by flow cytometry and 3 brains 
by histology. For flow cytometry, 5 mm3 of the tumor-bearing as well as the contralateral 
hemisphere were dissociated in single cell suspension. For histology, 8 µm cryostat 
sections were stained with H&E and antibodies to vWF (Dako Cytomation) or to CD62E 
(BD Biosciences). Nuclei were counterstained with 4`,6-diamidino-2-phenylindole 
(Vectashield with DAPI, Vector Laboratories, Axxora GmbH, Loerrach, Germany). 
 
Statistical analysis 
Quantitative data were obtained for migration, ELISA, flow cytometry and reporter 
assays as indicated. Data are expressed as mean and SEM. Statistical significance was 
assessed by one-way ANOVA followed by Tukey’s post hoc test (Excel, Microsoft, 
Seattle, WA, USA). The experiments reported here were performed at least three times 
in triplicate with similar results. 
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Results 
 
Transendothelial HPC migration is enhanced after pretreatment of endothelial 
cells with SN-G  
The molecular signature of endothelial cells depends on the environment. Endothelial 
cells from vessels within normal tissue are different from endothelial cells of vessels 
within an inflamed or neoplastic tissue (Frenette et al., 1996). To simulate the 
conditioning of endothelial cells of vessels within glioblastoma tisssue in vitro, we 
cultured cerebral endothelial cells (SV-HCEC) or human microvascular enodothelial cells 
(HMEC) in SN of LNT-229, LN-308, T113, T159 (derived from glioblastomas) or T132 
(derived from anaplastic astrocytoma) glioma cells. Further, we used brain tumor 
endothelial cells (BTEC) from human glioblastoma specimens. HPC migrated through an 
untreated SV-HCEC-, HMEC (data not shown) and BTEC layer (Fig. 1). The migration 
was significantly enhanced after the preincubation of all three types of endothelial cell 
layer with different SN-G. Pretreatment of the SV-HCEC, HMEC (data not shown) and 
BTEC with hypoxia and irradiation also increased the migration of HPC. Incubation with 
SN of the astrocytic cell line SV-FHAS (SN-FHAS), however, did not modulate 
transendothelial migration. Thus, SN-G, hypoxia or irradiation alter the characteristics of 
endothelial cells and hence promote the transendothelial migration of HPC.  
 
SN-G induces the expression of CD62E on SV-HCEC and HMEC 
To understand the increase in transendothelial HPC migration, we performed flow 
cytometry for the detection of VCAM-1 and CD62E on SV-HCEC, HMEC or BTEC either 
un- or pretreated with SN-G, irradiation or hypoxia. Untreated SV-HCEC, HMEC and 
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BTEC constitutively expressed VCAM-1 at SFI values of 1.8, 1.7 and 1.9. The 
expression of VCAM-1 was not altered after pretreatment of the endothelial cells with 
SN-G, irradiation or hypoxia (data not shown). In contrast, CD62E was expressed on 
untreated BTEC but not on untreated SV-HCEC or HMEC. However, SN-G enhanced or 
induced the expression of CD62E as did hypoxia or irradiation (Fig. 2). Pretreatment 
with vascular endothelial growth factor (VEGF)165 served as a positive control.  
 
Endothelial cells of tumor vessels in human astrocytomas but not normal brain 
vessels highly express CD62E  
To confirm the relevance of CD62E induction on endothelial cells in vitro, we performed 
immunohistochemistry on TMA sampling normal brain sections, diffuse astrocytomas 
(WHO grade II), anaplastic astrocytomas (WHO grade III) and human glioblastomas 
(WHO grade IV). Normal brain tissue contains small capillaries and vessels whereas the 
vessels in glioblastomas are characteristically composed of enlarged and thickened 
endothelial cell layers. CD31 staining labeled endothelial cells within the vessel walls of 
normal and neoplastic tissue. CD62E immunoreactivity was absent on endothelial cells 
of blood vessels within normal human brain samples. In contrast, CD62E was present in 
all neoplastic samples. CD62E strongly correlated with blood vessel morphology: Large 
vascular proliferations in glioblastoma samples showed the strongest CD62E 
immunoreactivity whereas smaller, more regular blood vessels found in the same tumors 
displayed a weaker CD62E staining intensity (Fig. 3). A slight cytoplasmic CD62E 
staining was detected in tumor cells of most tumor samples. This prompted us to 
determine the concentration of soluble CD62E (sCD62E) in SN-G and in SN of 
endothelial cells in vitro by ELISA. SN of BTEC harvested after 96 h contained sCD62E 
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(70 + 10 pg/ml) whereas SN-G and SN of untreated SV-HCEC and HMEC did not. In 
contrast, 96 h after stimulating SV-HCEC and HMEC with SN-G, sCD62E was detected 
in the SN of these endothelial cells (50 - 70 pg/ml). Thus, CD62E shedding and release 
of sCD62E may account for the apparent cytoplasmic staining observed in astrocytoma 
samples (Fig 3).  
 
Enhanced migration of HPC through an SV-HCEC layer in vitro depends on CD62E  
We next investigated the role of HPC adhesion to CD62E for transendothelial HPC 
migration through an SN-G-conditioned endothelial cell layer. We studied the 
transendothelial migration in the absence or presence of neutralizing antibodies to 
CD62E either with or without pretreatment of the endothelial cell layer. Neutralizing 
CD62E reduced the transendothelial HPC migration significantly (Fig. 4A, first panel). 
Because of the important regulatory role of TGF-β for HPC glioma tropism (Tabatabai et 
al., 2006), we also investigated the role of TGF-β in the transendothelial HPC migration 
by targeting TGF-β expression and TGF-β signaling in glioma cells. We used stably 
transfected LNT-229 siTGF-β1,2 cells (Friese et al., 2004; Eisele et al., 2006) or siRNA 
pools targeting TGF-β1 and TGF-β2 ,respectively, for transient transfection of LN-308 
before collection of SN-G.  
Transendothelial HPC migration through endothelial cells that had been pretreated with 
SN of LNT-229 siTGF-β1,2 (SN-GsiTGF-β), was reduced and neutralizing α-CD62E did 
not modulate HPC migration (Fig. 4A, second panel). Further, transient transfection of 
LN-308 glioma cells with siRNA pools targeting TGF-β1 and TGF-β2 respectively inhibited 
TGF-β1 and TGF-β2 release into the SN (Fig 4B). Combined targeting of TGF-β1 and 
TGF-β2 in LN-308 cells inhibited the phosphorylation of Smad2 (Fig 4B) indicating 
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abrogation of TGF-β signaling. HPC migration through endothelial cells that had been 
pretreated with SN of these cells was accordingly reduced and neutralizing CD62E did 
not modulate the migration (Fig. 4 A, third and fourth panel). 
Preirradiation of the endothelial cells resulted in an enhancement of transendothelial 
HPC migration (Fig. 1) that was also reduced by neutralizing CD62E antibodies (Fig. 
4C). In contrast, neutralizing VCAM-1 antibodies did not significantly reduce HPC 
migration through an untreated SV-HCEC- or BTEC and an SN-G-treated SV-HCEC 
layer (Table 1).  
 
Homing of murine HPC to orthotopically implanted SMA-560 gliomas in vivo is 
reduced after neutralization of CD62E 
We next investigated the role of CD62E for the glioma tropism of murine HPC in an 
orthotopic syngeneic glioma model in vivo. 104 SMA-560 glioma cells were implanted 
into the right striatum of VM/Dk mice. On day 8, 106 PKH-26 stained LSK cells were 
injected intravenously. Four h before and 4 h after injection of LSK, CD62E-neutralizing 
antibodies (6 mice) or control antibodies (6 mice) were bolus-injected both 
intraperitoneally and intratumorally in parallel in the same animals to block adhesion. On 
day 10, the brains were removed. Three brains per group were used for assessment by 
flow cytometry, 3 brains were analyzed by histology. Injection of CD62E and control 
antibodies did not affect tumor morphology, tumor growth or vessel density as assessed 
by H&E or vWF (Fig. 5A). The endothelial cells of tumor vessels expressed CD62E (Fig. 
5 A). Fluorescence staining showed reduced amount of PKH26-labeled LSK within the 
SMA-560 glioma after pretreatment with anti-CD62E antibodies (Fig. 5 B). Single-cell 
suspension of freshly removed samples of the SMA-560 gliomas or of the contralateral 
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hemisphere were analyzed by flow cytometry to detect the amount of PKH26-labeled 
LSK. Co-treatment with anti-CD62E antibody reduced the amount of PKH26-positive 
LSK in orthotopic SMA-560 gliomas (Fig. 5 C). 
 
TGF-β signaling in glioma cells is required for SN-G-mediated induction of CD62E 
expression on SV-HCEC 
We next characterized the time course of de novo CD62E expression by SV-HCEC and 
HMEC. TNF-α treatment (100 U/ml) served as a positive control. This treatment resulted 
in high expression of CD62E by SV-HCEC (Fig. 6 A) and HMEC (Fig. 6 B) after 6 h, then 
declining within the next 90 h. Similarly, treatment with VEGF165 (40 ng/ml) resulted in 
high CD62E expression after 6 h which was no more detectable 96 h after treatment. 
Culturing of SV-HCEC or HMEC in SN of the astrocytic cell line SV-FHAS did not induce 
CD62E expression. Treatment of SV-HCEC or HMEC with SN-G resulted in a maximum 
CD62E expression at 12 h (Fig 6 A, B).  
We next analyzed the role of TGF-β signaling for the induction of CD62E. The treatment 
of SV-HCEC with recombinant TGF-β2 (10 ng/ml) alone did not induce CD62E 
expression (Fig. 7A). Then, we collected SN of glioma cells that had been pretreated 
with the TGF-β receptor I kinase inhibitor, SD-208 (0.1 µmol/l and 1.0 µmol/l). SD-208 
treatment blocked TGF-β signaling in LN-308, T113 and T132 cells (Fig. 7B). The 
exposure of SV-HCEC to SN of these SD-208-treated glioma cells did not induce 
CD62E expression (Fig. 7A). In accordance, exposure of SV-HCEC to SN-308 siTGF-
β1,2 (Fig. 4A,B) did not induce CD62E (Fig. 7A). Finally, we also treated LNT-229 siTGF-
β1,2 cells stably depleted from TGF-β1 and TGF-β2 (Friese et al., 2004) with recombinant 
TGF-β2 (10 ng/ml) for 7 days to rescue TGF-β signaling in these glioma cells (Friese et 
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al., 2004; Tabatabai et al., 2005; Eisele et al., 2006). SN from these cells again induced 
CD62E on SV-HCEC (Fig. 7A). In contrast, the treatment of SV-HCEC with SN-G in the 
presence of SD-208 (0.1 µmol/l and 1.0 µmol/l), which abrogates TGF-β signaling 
pathway in SV-HCEC and HMEC (Fig. 7C), did not influence the SN-G-mediated 
induction of CD62E. The exposure of endothelial cells with SN-GRT or SN-GHO led to 
the induction of CD62E, too. This effect was again prevented by SD-208 treatment of the 
glioma cells before harvesting the SN (data not shown).  
The experiments involving the addition of recombinant TGF-β2 or SD-208 indicate that (i) 
TGF-β signaling in glioma cells is required for the induction of CD62E on endothelial 
cells, but (ii) TGF-β signaling in SV-HCEC is not involved in SN-G-mediated induction of 
CD62E expression.  
 
Induced CD62E expression on SV-HCEC is mediated by VEGF-R2 signaling  
We next analyzed the levels of VEGF, a candidate inducer of CD62E expression, in 
concentrated SN-Gp and SN-GsiTGF-β treated with or without SD-208 or TGF-β2 (Table 
2). VEGF release was reduced by abrogated TGF-β signaling. In contrast, addition of 
recombinant TGF-β2 to LNT-229 siTGF-β1,2 cells for 7 days before generation of SN 
restored VEGF levels in the SN. Further, irradiated and hypoxic SV-HCEC released 
increased levels of VEGF (Table 2). SV-HCEC, HMEC and BTEC expressed the 
corresponding receptor VEGF-R2 (Fig.8A). Therefore, we analyzed the role of 
VEGF/VEG-R2 signaling in endothelial cells for CD62E induction. Treatment of SV-
HCEC, HMEC and BTEC with VEGF165 , SN-G, hypoxia or irradiation increased the level 
of phosphorylated VEGF-R2 (Fig. 8 B). The level of total VEGF-R2 in untreated SV-
HCEC (597 pg/ml) did not increase by exposure of SV-HCEC to VEGF165 (590 pg/ml) or 
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SN-308 (572 pg/ml). Pretreatment with hypoxia, 2 Gy or 8 Gy, however, increased the 
amount of total VEGF-R2 in SV-HCEC (807, 992 and 2670 pg/ml). Similarly, the amount 
of total VEGF-R2 in untreated HMEC (664 pg/ml) was not increased by VEGF165 (579 
pg/ml), SN-308 (660 pg/ml), whereas hypoxia (772 pg/ml), irradiation at 2 Gy (1222 
pg/ml) or 8 Gy (2982 pg/ml) led to elevated amounts of total VEGF-R2 protein in HMEC. 
In BTEC, we detected levels of total VEGF-R2 in untreated (502 pg/ml), hypoxic (452 
pg/ml) or irradiated cells (2 Gy: 459, 8 Gy 449 pg/ml). These data indicate, that VEGF-
R2 signaling activity in SV-HCEC, HMEC, BTEC is further enhanced after exposure to 
the indicated treatments. Targeting of VEGF in glioma cells by siRNA pools led to a 
reduced VEGF release by LN-308 glioma cells and T113 primary glioma culture (Fig. 
8C). VEGF levels are reduced in SN-308 TGF-β1,2 (Fig. 8C) and SN of LNT-229 after 
inhibition of TGF-β signaling (Table 2). The SN-G-mediated de novo expression of 
CD62E was prevented by SN-308 siVEGF and by the addition of neutralizing VEGF- or 
VEGF-R2 antibodies (Fig. 8D). Further, the exposure of SV-HCEC to irradiation or SN-
G, SN-GRT, SN-GHO supplemented with neutralizing α-VEGF and α-VEGF-R2 
antibodies inhibited CD62E induction (data not shown). 
From these experiments, we concluded: First, SN-G enhances VEGF-R2 signaling 
activity in endothelial cells; second, VEGF from SN-G, SN-GHO or SN-GRT is required 
for the SN-G-induced expression of CD62E in SV-HCEC; third, VEGF release from SV-
HCEC is required for CD62E induction after exposure to hypoxia or RT.  
 
Transcriptional activation of CD62E in endothelial cells is mediated by nuclear 
factor kappa B (NFκB) 
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The promoter of CD62E contains multiple NFκB- binding sites (Schindler et al., 1994). 
We detected NFκB p65 and p50 in whole cell lysates of SV-HCEC (Fig. 9A). Protein 
levels were not modulated by irradiation, hypoxia or pretreatment with SN-Gp, SN-
GsiTGF-β or SN-GRT. Futher, we analyzed the activation of the NFκB transcription 
family in nuclear extracts of BTEC, SV-HCEC and HMEC (Fig. 9B). Raji extracts served 
as positive control, nuclear extracts from NIH3T3 cells were used as negative controls. 
The NFκB transcription family is activated in untreated endothelial cells. We next 
analyzed the activity of p50 in nuclear extracts of endothelial cells after treatment with 
VEGF165 or SN-G. TNF-α served as positive control (Fig. 9C). VEGF165 and SN-G 
further increased the transcriptional activity of p50, whereas treatment with SN-308 
siVEGF did not. In addition, we performed reporter assays with pNFκB-luc. This plasmid 
contains four copies of the NFκB consensus sequence and detects the transcriptional 
activity of NFκB. Treatment with TNF-α (100 U/ml) served as a positive control (Fig. 
9,10). The relative luciferase activity of pNFκB-luc in untreated BTEC, SV-HCEC and 
HMEC demonstrates the baseline transcriptional activity (Fig. 9D) in accordance with the 
data of the transAM assay (Fig. 9B,C). After exposure to TNF-α, VEGF165 or SN-G, 
NFκB transcriptional activity significantly increased (Fig. 10). Neutralizing antibodies to 
VEGF and VEGF-R2 reduced SN-G-induced NFκB transcriptional activity.  
In parallel, we analyzed the activity of the CD62E promoter by measuring the relative 
luciferase activity of pGL3basic.CD62E. In this plasmid, the reporter gene is driven by 
the CD62E promoter and indicates the activity of the CD62E promoter. In untreated SV-
HCEC and HMEC, no luciferase activity was detectable, indicating a lack of CD62E 
promoter activity in this cell population (Fig. 9D). However, after treatment with TNF-α, 
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VEGF165 or SN-G, the relative luciferase activity of pGL3.basic.CD62E increased (Fig. 
10). Irradiation with 2 Gy, 8 Gy or hypoxia also increased pGL3.basic.CD62E activity 
(data not shown). NFκB transcriptional activity and CD62E promoter activity were 
diminished by neutralizing α-VEGF and α-VEGF-R2 antibodies (Fig. 10). To analyze 
whether NFκB transcriptional activity is required for CD62E promoter activity, we 
performed reporter assays after targeting NFκB by the NFκB-super-repressor Ad-IKBM. 
We transduced SV-HCEC with 100 MOI of Ad-IKBM. Ad-Mock served as control. 
Relative luciferase activity of pGL3.basic.CD62E in SV-HCEC was not induced by SN-G 
in the presence of the NFκB-super-repressor (Fig 10). These experiments place VEGF 
signaling and NFκB upstream of the transcriptional activation of CD62E in SV-HCEC. 
The presumptive signaling cascade leading to the induction of CD62E in SV-HCEC by 
SN-G, irradiation or hypoxia is summarized schematically in Fig. 11. 
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Discussion 
 
Adult HPC migrate towards experimental gliomas. Therefore, this adult stem cell 
population might be a promising cellular vector for the delivery of therapeutic molecules 
to experimental gliomas. Before applying therapeutic approaches, however, the 
underlying molecular mechanisms of the glioma-mediated HPC attraction should be 
better understood. The objective in characterizing the glioma tropism of HPC is to 
achieve an optimal seeding of experimental gliomas with HPC. Adhesion molecules 
expressed on endothelial cells serve as keys to allow the entrance of circulating cells at 
specific tissue sites (Frenette et al., 1996a,b). BM- and umbilical cord blood-derived 
CD34+ HPC adhere to CD62E on BM microvasculature (Najer et al., 1999, Dimitroff et 
al., 2001, Hidalgo et al., 2002). P- and E-selectin-deficient mice exhibit severe 
deficiencies in hematopoiesis (Frenette et al., 1996). Intravital microscopy studies show 
that P- and E-selectin contribute to HPC rolling in the BM microvasculature. Blocking 
both selectins and VCAM-1 inhibits the rolling interaction almost completely (Mazo et al., 
1998). Hidalgo et al. (2002) demonstrated by fluorescence intravital microscopy and 
homing assays in NOD/SCID mice that endothelial selectins are necessary for CD34+ 
HPC homing: Rolling on BM endothelium and retention in the BM compartment are 
severely reduced in CD62E–deficient NOD/SCID mice. Thus, homing of HPC to the BM 
is mediated by HPC interactions with multiple adhesion receptors. Among these, CD62E 
and VCAM-1 are expressed preferentially on endothelial cells. Therefore, we focussed 
on investigating the possible contribution of CD62E and VCAM-1 to HPC glioma tropism. 
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CD62E expression by glioma-conditioned endothelial cells in vitro and in vivo  
We used three different endothelial cell types: the cerebral endothelial cell line SV-
HCEC (Muruganandam et al., 1997), the endothelial cell line HMEC and brain tumor 
endothelial cells (BTEC). BTEC were isolated from freshly resected glioblastomas as 
described (Miebach et al., 2004). These endothelial cells constitutively expresses 
VCAM-1, but not CD62E. In the BM microvasculature, CD62E and VCAM-1 are 
constitutively expressed (Schweitzer et al., 1996). In most other tissues, however, 
CD62E is transcriptionally regulated and expressed on the surface after exposure to 
specific inflammatory stimuli (Bevilacqua et al., 1989). We found CD62E expression on 
untreated BTEC. De novo CD62E expression was by SV-HCEC and HMEC occurred 
after stimulation with SN-G, SN-GHO, SN-GRT as well as treatment with hypoxia (Fig. 
2) or irradiation. The constitutive VCAM-1 expression on the endothelial cells was not 
altered by these treatments. These results differ from studies with BM microvasculature: 
Total body irradiation of mice increased VCAM-1 expression, but the constitutive 
expression level of CD62E within the BM microvasculature was unchanged (Mazo et al., 
2002). Having observed an SN-G-induced CD62E expression by SV-HCEC and HMEC 
in vitro, we analyzed CD62E expression in situ. The endothelium of vessels within 
astrocytoma tissue of WHO grades II – IV highly expressed CD62E whereas CD62E 
staining was absent in normal brain (Fig. 3). In addition to the well-defined CD62E 
staining of tumor endothelium, there was a diffuse extracellular and cytoplasmic staining 
in the neoplastic specimens. This might indicate the shedding of CD62E and the 
presence of the soluble form of CD62E (Oh et al, 2007). In that regard, we also detected 
sCD62E in SN of stimulated SV-HCEC, HMEC and in SN of untreated BTEC in vitro. 
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CD62E is one mediator of the glioma-mediated HPC attraction in vitro and in vivo 
The transendothelial migration of HPC was significantly diminished in the presence of 
neutralizing CD62E antibodies (Fig. 4) whereas neutralizing VCAM-1 antibodies had no 
such effect. In vivo, administration of a CD62E blocking antibody reduced the amount of 
PKH26-positive LSK in orthotopic SMA-560 gliomas (Fig. 5) indicating that CD62E is at 
least in part one mediator of the glioma tropism of LSK in vivo. In a model of chronic 
kidney disease, Gong et al. (2006) demonstrated de novo CD62E expression in renal 
vascular endothelium mediating leucocyte adhesion. The bolus injection of neutralizing 
CD62E antibodies diminished interstitial inflammation and macrophage sequestration in 
the kidney in vivo. Recently, Nishiwaki et al. (2007) demonstrated a crucial role for 
CD62E in the interaction between circulating EPC and vessel endothelium in the mouse 
hind-limb ischemia paradigm. Oh and colleagues (2007) demonstrated that CD62E is a 
pivotal molecule for EPC homing to the ischemic site and for vasculogenesis in an 
ischemic limb model. Based on these data, a novel cell-based therapy for ischemic 
atherosclerosis might be designed.  
 
SN-G-mediated induction of CD62E requires TGF-β signaling in glioma cells and 
VEGF / VEGF-R2 signaling in endothelial cells  
We next investigated the molecular mechanism mediating the de novo expression of 
CD62E in SV-HCEC or HMEC. Culturing of SV-HCEC with SN-GsiTGF-β did not induce 
CD62E expression (Fig. 7). HPC migration through an SN-GsiTGF-β-treated SV-HCEC 
layer was not altered by neutralizing α-CD62E. The reduction of relative HPC migration 
(Fig 4a) observed after pretreating SV-HCEC with SN-GsiTGF-β can be explained by 
the lack of CD62E expression (Fig. 7). Based on this observation, we analyzed the role 
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of TGF-β signaling in the glioma-mediated induction of CD62E. When TGF-β signaling 
was inhibited in LNT-229 glioma cells before SN collection – either by SD-208 or by 
siRNA - these SN did not induce CD62E expression (Fig. 7). Inhibition of TGF-β 
signaling in SV-HCEC or HMEC by SD-208, however, did not modulate SN-G-mediated 
CD62E induction. Further, treatment of SV-HCEC with recombinant TGF-β2 alone did 
not to induce CD62E (Fig. 7). We concluded that glioma-mediated CD62E induction 
requires intact TGF-β signaling in the glioma cells, but not in SV-HCEC. Inhibition of 
TGF-β signaling in glioma cells also led to diminished VEGF levels (Table 2, Fig. 8C). 
Irradiation with 2 or 8 Gy and preexposure to hypoxia on the other hand increased 
VEGF secretion by SV-HCEC and HMEC (Table 2). We therefore analyzed the influence 
of VEGF / VEGF-R2-signaling on CD62E induction in SV-HCEC. Treatment of SV-
HCEC and HMEC with SN of glioma cells that had been transfected with siRNA pools 
targeting VEGF did not induce CD62E (Fig. 8D). Neutralization of VEGF or VEGF-R2 
bioactivity impaired SN-G-mediated CD62E induction (Fig. 8D), indicating a pivotal role 
of this signaling pathway in SV-HCEC or HMEC for the induction of CD62E expression. 
Recently, Stannard et al. (2007) demonstrated that VEGF primes endothelial cells by 
sensitizing them to cytokines, leading to enhanced selective pro-inflammatory 
responses, including upregulation of CD62E.  
 
De novo expression of CD62E by endothelial cells is mediated by NFκB 
To further characterize the downstream events after VEGF-R2 activation, we performed 
reporter assays. SN-G, irradiation or hypoxia induced CD62E promoter activity in SV-
HCEC. Since the CD62E promoter contains three NFκB binding sites (Schindler et al., 
1994), we analyzed the role of NFκB in our pradigm. NFκB is expressed and 
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transcriptionally active in SV-HCEC, HMEC and BTEC (Fig. 9, 10). NFκB is also 
activated in presheared HUVEC leading to NFκB- dependent cytoprotective 
responsiveness (Patridge et al., 2007). Consequently, we investigated the upstream 
control of CD62E promoter activity with the NFκB super repressor, Ad-IkBM. Inhibition of 
NFκB acitivity strongly reduced CD62E promoter activity (Fig. 10). This central role of 
NFκB acitivity for CD62E induction in our studies parallels results in other models: 
Endothelial cell activation by HIV infection results in CD62E expression via a Tat-
induced NFκB-mediated pathway (Cota-Gomez et al., 2002). CD62E induction within an 
artherosclerotic lesion is evoked by the platelet-specific chemokine 4 derived from 
platelets and activation of NFκB was crucial for CD62E induction on endothelium by 
platelet-specific chemokine 4 (Yu et al., 2005). 
 
In summary, we define a signaling cascade leading to CD62E induction on endothelial 
cells in response to treatment with SN-G, SN-GHO, SN-GRT, irradiation or hypoxia. This 
cascade involves a TGF-β-dependent release of VEGF by glioma cells and the 
subsequent activation of VEGF-R2 in endothelial cells, resulting in an NFκB-mediated 
CD62E expression. We observed a selective expression of this adhesion molecule in 
human astrocytoma samples of WHO grades II-IV and demonstrated the functional 
relevance of CD62E for transendothelial HPC migration in vitro and in vivo. Therefore, 
we conclude that adhesion to CD62E on tumor endothelium might be a pivotal first step 
in the glioma tropism of HPC. Given the central role of VEGF in the glioma-mediated 
induction of CD62E on endothelial cells, a putative HPC-based therapy against 
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glioblastomas might not be effective in combination with antiangiogenic strategies 
targeting VEGF, e.g. enzastaurin or bevacizumab.  
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Table 1: Transendothelial HPC migration: no modulation by VCAM antibodies 
Treatment of monolayer Chemoattractant HPC migration [fold increase] 
 SFM 1 
SV-HCEC, untreated CXCL12 3,1  
 SN-G 7,1 
 SFM 1 
SV-HCEC, α-VCAM-1 CXCL12 3 
 SN-G 6,9 
 SFM 1,6 
SV-HCEC, SN-G CXCL12 6,5 
 SN-G 11,6 
 SFM 1,2 
SV-HCEC, SN-G + α-VCAM-1 CXCL12 6,1 
 SN-G 11,3 
 SFM 1 
BTEC, untreated CXCL12 8 
 SN-G 8.5 
 SFM 1 
BTEC, + α-VCAM-1 CXCL12 7.5 
 SN-G 8 
CD34+HPC (105) were added to the upper compartment of an endothelial cell 
monolayer-covered transwell insert. The monolayer was either untreated or stimulated 
with SN-G. SFM, CXCL12 (100 ng/ml) or SN of LNT-229 cells were added to the bottom 
wells. Relative transendothelial migration, i.e. migration related to basal migration 
towards SFM through the untreated monolayer, was determined 16 h later with or 
without neutralizing α-VCAM1-antibodies (mean, n = 3, SEM < 10%). 
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Table 2: Modulation of VEGF release by LNT-229 and SV-HCEC 
Concentrated Supernatants VEGF [pg/ml] 
LNT-229  390 
LNT-229 puro 410 
LNT-229 puro, pretreated with DMSO 400 
LNT-229 puro, pretreated with SD-208 85 
LNT-229 siTGF-β1,2 94 
LNT-229 siTGF-β1,2 treated with recombinant TGF-β2 370 
SV-HCEC  50 
SV-HCEC, 1% O2 , 12 h 610 
SV-HCEC, 1% O2 , 24 h 920 
SV-HCEC, 2 Gy 680 
SV-HCEC, 8 Gy 750 
 
VEGF protein levels were determined in concentrated SN by ELISA. The cells were 
either untreated, preincubated with SD-208 (1 µmol/l, 24 h) or vehicle, TGF-β2 (10 ng/ml, 
7 days), exposed to 1% O2 for 12 h and 24 h or preirradiated (2 Gy, 8 Gy, 48 h before 
harvest of SN) (mean, n = 5, p < 0.01, SEM < 10%). 
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Table 3: Clinical data  
 
Origin of tissue Number Median age 
(range)  
[years] 
Female Male 
Normal brain 
 
33 brains 
60 samples 
50.3 
(22 – 77) 
15 18 
Diffuse Astrocytoma  
WHO grade II 
10 tumors 
10 samples 
39.4 
(5 – 72) 
3 7 
Anaplastic Astrocytoma 
WHO grade III 
10 tumors 
10 samples 
44.7 
(12 – 67) 
- 10 
Glioblastoma 
WHO grade IV 
88 tumors 
120 samples 
58.1 
(23 – 88)  
35 53 
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Legends to the figures 
 
Fig. 1 Transendothelial migration of HPC through an SV-HCEC and BTEC layer 
SV-HCEC or BTEC, either untreated or pretreated with SN-G, hypoxia (HO) at 1% O2 for 
24 h or irradiation at 2 Gy and 8 Gy, were seeded on the transwells of a chemotaxis 
chamber. HPC (105) were added to the upper chamber. SFM, CXCL12 or SN of LNT-
229 were added to the lower compartment. HPC migration was assessed 16 h later. The 
bars indicate mean HPC migration relative to migration towards SFM through an 
untreated SV-HCEC layer and SEM (n=3, # p<0.05 compared with untreated SV-HCEC 
layer/SFM bottom well; * p<0.05 compared with untreated SV-HCEC layer/CXCL12 
bottom well; ~ p<0.05 compared with untreated BTEC layer/CXCL12 in bottom well).  
 
Fig. 2 Flow cytometry demonstrates modulation of endothelial CD62E expression 
by SN-G, hypoxia or irradiation 
CD62E expression was analyzed on the surface of endothelial cells without treatment, 
after stimulation with SN of LNT-229 for 48 h, 1% O2 for 24 h, irradiation at 2 Gy and 8 
Gy as well as pretreatment with VEGF165 (40 ng/ml) for 24 h.  
 
Fig. 3 Endothelial cells of human astrocytoma vessels highly express CD62E 
Representative samples of normal brain tissue, diffuse astrocytoma (WHO grade II), 
anaplastic astrocytoma (WHO grade III) and glioblastoma are shown. Depicted are H&E 
staining, immunoreactivity for CD31 and CD62E and the isotype control for CD62E.  
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Fig. 4 Neutralizing CD62E antibodies diminish transendothelial HPC migration in 
vitro 
A, HPC migration through an SN-Gp-, SN-GsiTGF-β-, SN-308 co- or SN-308siTGF-β1,2 
treated SV-HCEC layer towards CXCL12 in the bottom well after addition of neutralizing 
CD62E antibodies (grey bars) or of the respective IgG isotype control was assessed 
(black bars) (*p<0.05 compared with IgG; +p<0.05 compared with SN-Gp; #p<0.05 
compared with SN-308co; co = non-targeting control siRNA pool). B, Immunoblot for 
detection of phospho Smad2, total Smad2 and GAPDH loading control; ELISA detecting 
TGF-β1 or TGF-β2 levels (NT = not treated, co = non-targeting control siRNA pool, 1 = 
transfected with siRNA pool targeting TGF-β1, 2 = transfected with siRNA pool targeting 
TGF-β2, 1&2 = co-transfection with siRNA pools targeting TGF-β1 and TGF-β2) . C, 
HMEC or BTEC were untreated or irradiated. HPC migration was assessed after the 
addition of neutralizing CD62E antibodies (grey bars) or the corresponding IgG isotype 
control (black bars) (*p<0.05 compared with IgG). 
 
Fig 5 Neutralizing CD62E antibodies diminish the attraction of murine HPC by 
orthotopic SMA-560 glioma in vivo 
A, Morphology of SMA-560 glioma was assessed by H&E. vWF staining was used for 
visualization of vessels. CD62E is expressed by tumor endothelial cells. Isotype controls 
for vWF and CD62E are displayed. B, Fluorescence microscopy after nuclear 
counterstaining with DAPI for the detection of glioma cells (blue) and PKH-26 stained 
LSK (red). After neutralizing CD62E (anti-CD62E), the number of LSK in gliomas is 
reduced as compared to isotype control (IgG). C, The amount of PKH26-stained LSK in 
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the SMA-560 glioma or in the contralateral hemisphere were quantified by flow 
cytometry. 
 
Fig. 6 Time-course of de novo CD62E expression by SV-HCEC and HMEC 
Flow cytometry was performed to investigate CD62E expression on SV-HCEC (A) or 
HMEC (B) at 6, 12, 24, 48 and 96 h after pretreatment as indicated.  
 
Fig. 7 The role of TGF-β signaling for the induction of CD62E expression 
A, Flow cytometry was performed to analyze CD62E expression of SV-HCEC at 12, 24 
h after the indicated pretreatments. B, Immunoblot for the detection of phospho Smad2, 
total Smad2 and GAPDH in lysates of LN-308, T113 or T132 after treatment with SD-
208. C, Immunoblot for the detection of phospho Smad2, total Smad2 and GAPDH in 
lysates of SV-HCEC or HMEC after treatment with SD-208. In B and C: NT = not 
treated, V = vehicle 1 µmol/l, 0.1 = SD-208 0.1 µmol/l, 1.0 = SD-208 1.0 µm0l/l) 
 
Fig. 8 The role of VEGF / VEGF-R2 signaling for the induction of CD62E 
expression 
A, Flow cytometry was performed to determine VEGF-R2 expression of SV-HCEC, 
HMEC and BTEC. B, The levels of phosphorylated VEGF-R2 in SV-HCEC, HMEC or 
BTEC were asssessed after the indicated pretreatments. C, ELISA was performed to 
evaluate the release of VEGF after the indicated treatments. D, CD62E expression was 
analyzed by flow cytometry at 6, 12 h after the indicated treatments. 
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Fig. 9: NFκB protein levels and transcriptional activity of NFκB family in 
endothelial cells 
A, Immunoblots show the expression of NFκB in lysates of SV-HCEC either untreated or 
after exposure to 1% O2, irradiation at 8 Gy, treatment with SN-GRT, SN-Gp or SN-
GsiTGF-β. GAPH was used as a loading control. B, Profiling of the transcriptional 
activity of the NFκB family in endothelial cells. C, Transcriptional activity of p50 was 
assessed in SV-HCEC or HMEC 24 h after the indicated treatments. D, Untreated 
BTEC, SV-HCEC or HMEC were transfected with NFκB-luc or pGL3b.CD62E. The bars 
indicate relative luciferase activity. 
 
Fig. 10 Transcriptional activation of CD62E by SN-G is mediated by NFκB 
SV-HCEC were transfected with NFκB-luc or pGL3b.CD62E either alone or tranduced 
with the NFκB super repressor Ad-IKBM or Ad-Mock. The cells were then treated with 
TNF-α, VEGF165 or SN as well as SN with neutralizing VEGF- or VEGF-R2 antibodies. 
The bars indicate relative luciferase activity (n=3, * p < 0.01 compared with 
pGL3b.CD62E). 
 
Fig. 11 Schematic overview of results 
De novo expression of CD62E on endothelial cells in response to a TGF-β dependent 
VEGF release by glioma cells involves the activation of VEGF-R2 in endothelial cells, 
resulting in an NFκB-mediated CD62E expression. VEGF also mediates the irradiation- 
or hypoxia-induced de novo expression of CD62E.  
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